PRLD
Prelude Therapeutics Incorporated
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-17/100
Last price
3.77
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.68
Prev close
3.77
Day high
3.82
Day low
3.68
Volume
382.43K
Market cap
$304.05M
P/E (TTM)
—
52W range
1.15 – 6.83
Day trading desk
Gap from prior close
-2.39%
Prior close 3.77
VWAP
3.79
-0.44% from price
Relative volume
1.51×
Unusually busy
Session range
4.62%
3.68 – 3.85
Position in range
53%
Mid range
ATR (14D)
0.30
7.97% of price
Prior day high
3.81
PDH
Prior day low
3.55
PDL
Bid / ask spread
—
Quote not published
Session volume
720.66K
Avg 476.23K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.79%
-5.7%
1M
-30.22%
-31.4%
3M
-25.59%
-30.1%
6M
-13.41%
-31.6%
YTD
+31.38%
+17.1%
1Y
+159.18%
+142.8%
3Y
+23.30%
-59.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PRLD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
14.17M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 21, 26 | BONITA DAVID P. Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 2.82M | $12.50M | Indirect |
| Apr 21, 26 | ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 2.82M | $12.50M | Indirect |
| Oct 3, 25 | HUANG JANE President |
— | 9.38K | — | Direct |
| Jul 3, 25 | HUANG JANE President |
— | 9.38K | — | Direct |
| Apr 4, 25 | HUANG JANE President |
— | 9.38K | — | Direct |
| Mar 25, 25 | VADDI KRISHNA Chief Executive Officer |
BUY | 675.00K | $467.44K | Direct |
| Mar 25, 25 | COMBS ANDREW P Officer |
BUY | 100.00K | $69.25K | Direct |
| Mar 21, 25 | VADDI KRISHNA Chief Executive Officer |
BUY | 20.42K | $14.91K | Direct |
| Mar 17, 25 | VADDI KRISHNA Chief Executive Officer |
BUY | 39.10K | $29.46K | Direct |
| Mar 13, 25 | VADDI KRISHNA Chief Executive Officer |
BUY | 97.50K | $69.56K | Direct |
| Jan 3, 25 | HUANG JANE President |
— | 9.38K | — | Direct |
| Dec 31, 24 | VADDI KRISHNA Chief Executive Officer |
BUY | 5.00K | $6.04K | Indirect |
| Dec 30, 24 | VADDI KRISHNA Chief Executive Officer |
BUY | 10.00K | $12.00K | Indirect |
| Dec 23, 24 | COMBS ANDREW P Officer |
BUY | 63.08K | $85.54K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BONITA DAVID P. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
COMBS ANDREW P |
Officer | 480.12K | Purchase |
HUANG JANE |
President | 86.92K | Conversion of Exercise of derivative security |
LIM BRYANT DAVID |
Chief Financial Officer | 27.40K | Purchase |
ORBIMED ADVISORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
VADDI KRISHNA |
Chief Executive Officer | 3.67M | Purchase |
Fundamentals
Market cap$304.05M
Enterprise value$258.30M
Revenue (TTM)$22.42M
Gross profit$22.42M
EBITDA$-64.51M
Net income$-60.49M
EPS (TTM)$-0.73
Free cash flow$-13.84M
Total cash$151.76M
Total debt$17.65M
Book value / share$1.30
Shares outstanding65.08M
Float22.06M
Short % of float14.33%
Dividend yield0.00%
Beta (5Y)0.96
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.93
PEG ratio—
Price / sales—
Price / book2.93
EV / revenue11.52
EV / EBITDA-4.00
Gross margin100.00%
Operating margin-270.93%
Profit margin-269.75%
Return on equity-57.73%
Return on assets-27.15%
Debt / equity13.20
Current ratio4.07
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $12.14M | $7.00M | $0 | $0 | +73.4% |
| Operating revenue | $12.14M | $7.00M | $0 | $0 | +73.4% |
| Research & development | $94.30M | $118.00M | $103.39M | $92.89M | -20.1% |
| Selling, general & admin | $22.41M | $28.72M | $28.88M | $30.65M | -22.0% |
| Total operating expense | $116.71M | $146.71M | $132.28M | $123.54M | -20.5% |
| Operating income | -$104.57M | -$139.71M | -$132.28M | -$123.54M | +25.2% |
| Pre-tax income | -$99.50M | -$127.17M | -$121.83M | -$115.44M | +21.8% |
| Net income | -$99.50M | -$127.17M | -$121.83M | -$115.44M | +21.8% |
| Net income to common | -$99.50M | -$127.17M | -$121.83M | -$115.44M | +21.8% |
| Basic EPS | -1.29 | -1.68 | -2.02 | -2.44 | +23.2% |
| Diluted EPS | -1.29 | -1.68 | -2.02 | -2.44 | +23.2% |
| EBIT | -$104.57M | -$139.71M | -$132.28M | -$123.54M | +25.2% |
| EBITDA | -$102.86M | -$137.94M | -$131.11M | -$122.22M | +25.4% |
| Basic shares | 76.96M | 75.81M | 60.36M | 47.37M | +1.5% |
| Diluted shares | 76.96M | 75.81M | 60.36M | 47.37M | +1.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $35.26M | $12.47M | $25.29M | $30.61M | +182.6% |
| Cash & short-term investments | $103.21M | $133.61M | $232.94M | $201.73M | -22.8% |
| Total current assets | $105.69M | $135.90M | $235.59M | $204.38M | -22.2% |
| Property, plant & equipment | $32.28M | $35.47M | $37.74M | $6.70M | -9.0% |
| Total assets | $141.31M | $175.51M | $277.67M | $220.50M | -19.5% |
| Total current liabilities | $52.99M | $25.64M | $21.83M | $21.70M | +106.7% |
| Total debt | $17.79M | $18.02M | $16.89M | $1.83M | -1.3% |
| Total liabilities | $72.68M | $44.06M | $40.58M | $25.06M | +65.0% |
| Retained earnings | -$683.06M | -$583.56M | -$456.39M | -$334.56M | -17.1% |
| Shareholder equity | $68.64M | $131.46M | $237.09M | $195.44M | -47.8% |
| Working capital | $52.70M | $110.25M | $213.76M | $182.68M | -52.2% |
| Net tangible assets | $68.64M | $131.46M | $237.09M | $195.44M | -47.8% |
| Shares issued | 62.95M | 55.15M | 54.91M | 47.90M | +14.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$99.50M | -$127.17M | -$121.83M | -$115.44M | +21.8% |
| Depreciation & amortisation | $1.71M | $1.77M | $1.17M | $1.32M | -3.4% |
| Stock-based compensation | $11.91M | $21.34M | $25.62M | $25.14M | -44.2% |
| Change in working capital | $28.41M | $4.22M | -$10.48M | $932.00K | +573.8% |
| Operating cash flow | -$56.30M | -$102.89M | -$107.06M | -$83.73M | +45.3% |
| Capital expenditure | -$67.00K | -$764.00K | -$3.51M | -$3.02M | +91.2% |
| Investing cash flow | $53.46M | $90.19M | -$34.65M | $81.69M | -40.7% |
| Financing cash flow | $24.82M | -$120.00K | $136.40M | $815.00K | +20,780.0% |
| Free cash flow | -$56.37M | -$103.65M | -$110.58M | -$86.75M | +45.6% |
| End cash position | $38.49M | $16.52M | $29.34M | $34.65M | +133.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $5.70M | $4.58M | $5.64M | $6.50M | $0 | — | +24.5% |
| Operating revenue | $5.70M | $4.58M | $5.64M | $6.50M | $0 | — | +24.5% |
| Research & development | $16.13M | $13.60M | $17.99M | $21.71M | $25.78M | — | +18.6% |
| Selling, general & admin | $5.03M | $5.16M | $5.00M | $5.21M | $6.41M | — | -2.5% |
| Total operating expense | $21.16M | $18.76M | $22.99M | $26.92M | $32.19M | — | +12.8% |
| Operating income | -$15.45M | -$14.18M | -$17.35M | -$20.42M | -$32.19M | — | -9.0% |
| Pre-tax income | -$13.92M | -$10.38M | -$16.46M | -$19.73M | -$31.23M | — | -34.0% |
| Net income | -$13.92M | -$10.38M | -$16.46M | -$19.73M | -$31.23M | — | -34.0% |
| Net income to common | -$13.92M | -$10.38M | -$16.46M | -$19.73M | -$31.23M | — | -34.0% |
| Basic EPS | -0.14 | -0.13 | — | -0.26 | -0.41 | -0.42 | -7.7% |
| Diluted EPS | -0.14 | -0.13 | — | -0.26 | -0.41 | -0.42 | -7.7% |
| EBIT | -$15.45M | -$14.18M | -$17.35M | -$20.42M | -$32.19M | — | -9.0% |
| EBITDA | -$15.10M | -$13.79M | -$16.93M | -$19.99M | -$31.76M | — | -9.5% |
| Basic shares | 98.39M | 82.52M | — | 76.13M | 75.99M | 75.99M | +19.2% |
| Diluted shares | 98.39M | 82.52M | — | 76.13M | 75.99M | 75.99M | +19.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.33M | $21.76M | $35.26M | $47.53M | $25.75M | +21.0% |
| Cash & short-term investments | $151.76M | $81.55M | $103.21M | $54.96M | $73.22M | +86.1% |
| Total current assets | $154.90M | $84.59M | $105.69M | $58.33M | $76.88M | +83.1% |
| Property, plant & equipment | $30.79M | $31.50M | $32.28M | $33.08M | $33.89M | -2.3% |
| Total assets | $189.36M | $119.64M | $141.31M | $94.75M | $114.92M | +58.3% |
| Total current liabilities | $38.04M | $41.72M | $52.99M | $18.19M | $20.91M | -8.8% |
| Total debt | $17.65M | $17.72M | $17.79M | $17.85M | $17.92M | -0.4% |
| Total liabilities | $55.63M | $59.46M | $72.68M | $36.22M | $39.08M | -6.4% |
| Retained earnings | -$707.37M | -$693.45M | -$683.06M | -$666.60M | -$646.88M | -2.0% |
| Shareholder equity | $133.73M | $60.18M | $68.64M | $58.53M | $75.84M | +122.2% |
| Working capital | $116.86M | $42.87M | $52.70M | $40.14M | $55.97M | +172.6% |
| Net tangible assets | $133.73M | $60.18M | $68.64M | $58.53M | $75.84M | +122.2% |
| Shares issued | 79.76M | 63.02M | 62.95M | 56.60M | 56.59M | +26.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$13.92M | -$10.38M | -$16.46M | -$19.73M | -$31.23M | — | -34.0% |
| Depreciation & amortisation | $353.00K | $391.00K | $418.00K | $425.00K | $433.00K | — | -9.7% |
| Stock-based compensation | $2.03M | $2.00M | $1.84M | $2.42M | $3.81M | — | +1.4% |
| Change in working capital | -$4.11M | -$13.69M | $37.12M | -$2.57M | $739.00K | — | +70.0% |
| Operating cash flow | -$15.57M | -$21.68M | $23.12M | -$19.11M | -$26.07M | — | +28.2% |
| Capital expenditure | — | — | — | — | -$20.00K | -$47.00K | — |
| Investing cash flow | -$65.50M | $8.50M | -$60.34M | $40.09M | $11.52M | — | -870.7% |
| Financing cash flow | $85.82M | -$314.00K | $24.94M | -$5.00K | $37.00K | — | +27,431.2% |
| Free cash flow | -$15.57M | -$21.68M | $23.12M | -$19.11M | -$26.09M | — | +28.2% |
| End cash position | $29.73M | $24.99M | $38.49M | $50.77M | $29.80M | — | +19.0% |
Options analytics
Put / call volume
0.01
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
5.00
+31.2% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-50.0%
Calls bid over puts
Call volume
203
Contracts, this expiry
Put volume
2
Contracts, this expiry
Heaviest call OI
5.00
0 contracts
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.19 | -0.14 | +24.3% |
| Mar 2026 | -0.27 | -0.13 | +51.2% |
| Dec 2025 | -0.18 | -0.20 | -11.1% |
| Sep 2025 | -0.36 | -0.26 | +26.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.15 | 2 | $37.00M | +469.2% |
| Next quarter | -0.16 | 2 | $3.56M | -36.8% |
| Current year | -0.58 | 3 | $43.56M | +258.8% |
| Next year | -0.55 | 3 | $41.77M | -4.1% |
Analyst targets & ownership
Mean target$9.20
High target$12.00
Low target$6.00
Implied upside144.03%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy2 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders13.76%
Held by institutions76.42%
Institutions holding105
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.90
-3.32% from price
SMA 20
4.30
-11.31% from price
SMA 50
4.98
-23.49% from price
SMA 100
4.64
-18.74% from price
SMA 200
3.90
-2.38% from price
EMA 12
4.04
-6.64% from price
EMA 26
4.42
-14.76% from price
EMA 50
4.64
-18.78% from price
RSI (14)
34.2
Neutral
MACD (12,26,9)
-0.38
Hist -0.04
ATR (14)
0.30
7.88% of price
Realised vol 30D
70.4%
Annualised
Bollinger upper
5.16
20, 2σ
Bollinger lower
3.43
20, 2σ
50 / 200 cross
Golden
4.98 vs 3.90
Trend bias
Below 200
-2.38%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.91
More volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
70.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-70.1%
Peak to trough
Max drawdown 5Y
-96.8%
Peak to trough
ATR 14
0.30
7.88% of price
Beta (reported)
0.96
5Y monthly, from filing
Short interest
Shares short
3.63M
Prior 3.82M
Change vs prior
-5.0%
Shorts covering
% of float
14.33%
Elevated
% of shares out
4.54%
Against total outstanding
Days to cover
6.8
Crowded exit
Float
22.06M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 17, 26 | JP Morgan | INITIATED | — | Overweight |
| Jul 29, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 4, 26 | D. Boral Capital | INITIATED | — | Buy |
| Apr 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 11, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Sep 23, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 18, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| May 5, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 29, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Apr 8, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 12, 25 | Citizens Capital Markets | MAINTAINED | Market Outperform | Market Outperform |
| Dec 11, 24 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-06-10
Periodic Financial Reports
10-Q · 2026-05-12
Annual Report to Shareholders
ARS · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-04-21
Corporate Changes & Voting Matters
8-K · 2026-04-20
Corporate Changes & Voting Matters
8-K · 2026-04-15
Headlines
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 26d ago
Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial
MT Newswires · 27d ago
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
GlobeNewswire · 27d ago
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
Stocktwits · 56d ago
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
Zacks · 68d ago
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Zacks · 82d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.